How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2175-2181

  Thanou, Aikaterini ^a   Chakravarty, Eliza ^a   James, Judith A ^a,b   Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

BILAG; Medications; Outcome measures; Physician's global assessment; Revised SELENA flare index; SELENA SLEDAI flare index; SLEDAI; Systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; GLUCOCORTICOID;

ARTICLE; CLINICAL DECISION MAKING; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICATION COMPLIANCE; MUSCULOSKELETAL DISEASE ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY OF ESTROGEN IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; DOSE RESPONSE; EVALUATION STUDY; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECURRENT DISEASE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; OKLAHOMA; PREDNISONE; RECURRENCE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84925226363     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu153     Document Type: Article

References (9)

1. Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
2. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
3. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
4. Isenberg DA, Allen E, Farewell V et al. An assessment of disease flare in patients with systemic lupus erythematosus:a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9.
5. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
6. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
7. Merrill J, Buyon J, Furie R et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709-16.
8. Merrill JT, Burgos-Vargas R, Westhovens R et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87.
9. Ruperto N, Hanrahan LM, Alarcon GS et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.